Hans‐Juergen Woerle

Roche (France) — France

Medicine · Health Sciences

35h-index5.7kcitations79works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(72), Pancreatic function and diabetes(36), Diabetes Management and Research(34), Metabolism, Diabetes, and Cancer(21), Peptidase Inhibition and Analysis(9)

Publications79 total

S75 A Study of Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of a Liquid Oral Formulation of NHS7108: A Novel Recombinant Lipase for the Treatment of Exocrine Pancreatic Insufficiency
The American Journal of Gastroenterology·2024
73-OR: The Plant-Based Substance Totum-63 (T63) Reduces Fasting Plasma Glucose and HbA1c in People with Prediabetes or Type 2 Diabetes (T2D)—A 24-Week Multicenter Randomized Controlled Trial (REVERSE-IT)
Diabetes·2024
Pharmacodynamics, safety, tolerability and pharmacokinetics of a single oral dose of an engineered phenylalanine ammonia-lyase in patients with phenylketonuria
Molecular Genetics and Metabolism Reports·2023· 3 citedOpen Access
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
Journal of the American Society of Nephrology·2018· 194 citedOpen Access
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction
publish.UP (University of Potsdam)·2018Open Access
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
Cardiovascular Diabetology·2018· 82 citedOpen Access
Abstract 18096: Interrelationship Between Reduction in Weight and Adiposity Indices and Improvement in Cardiovascular Death and Heart Failure Outcomes With Empagliflozin in Patients With Type 2 Diabetes in EMPA-REG OUTCOME
Circulation·2017
Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Diabetes Care·2017· 65 cited
ARE THE CARDIOVASCULAR RISK REDUCTIONS SEEN WITH EMPAGLIFLOZIN IN THE EMPA-REG OUTCOME TRIAL EXPLAINED BY CONVENTIONAL CARDIOVASCULAR RISK FACTORS?
Journal of the American College of Cardiology·2017· 1 cited
Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes
Pharmacogenetics and Genomics·2017· 47 citedOpen Access
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease　― Results From EMPA-REG OUTCOME<sup>®</sup> ―
Circulation Journal·2016· 123 citedOpen Access
Abstract 16903: Consistent Effect of Empagliflozin on Cardiovascular Death in Subgroups by Type of Cardiovascular Disease: Results From EMPA-REG OUTCOME
2016· 2 cited
Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia
Postgraduate Medicine·2016· 8 cited
Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial
Diabetes and Vascular Disease Research·2016· 9 citedOpen Access
EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK
Journal of the American College of Cardiology·2016· 1 cited
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes
Diabetologia·2015· 26 citedOpen Access
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
PLoS ONE·2015· 31 citedOpen Access
Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis
Canadian Journal of Diabetes·2015· 32 cited
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D<sup>™</sup> trial
Diabetes and Vascular Disease Research·2015· 42 citedOpen Access
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
Clinical Therapeutics·2015· 109 cited
page 1 of 4Next →

Frequent Co-authors

Maximilian von Eynatten(19), Sanjay Patel(18), Uli C. Broedl(13), Odd Erik Johansen(9), Julio Rosenstock(8), Ulrike Graefe‐Mody(8), Bernard Zinman(7), Yan Gong(6), Klaus A. Dugi(5), Per‐Henrik Groop(5), Vlado Perkovic(5), Angela Emser(5), Arne Ring(5), Tim Heise(4), David Z.I. Cherney(4), Bruce A. Perkins(4), Nima Soleymanlou(4), Sudipta Bhattacharya(4), Mark E. Cooper(4), Christoph Wanner(4)